# US 2026/0076913 A1 · Stabilized microcapsules, method of their preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076913 A1
- Document ID: US20260076913A1
- Status: Published application
- Kind: A1
- Application number: 19/399,157
- Filed: 2025-11-24
- Published: 2026-03-19
- Earliest claimed: 2020-05-22
- Assignees: Mayne Pharma LLC
- Applicants: Mayne Pharma LLC
- Inventors: Ofer TOLEDANO; Karine NEIMANN; Danil FINKEL-MOISEEV; Maya ERLICH; Dorit MARCO
- Web page: https://patentgrep.com/patent/US20260076913A1

## CPC

- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 9/4858: {Organic compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 9/501: {Inorganic compounds}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 9/5089: {Processes}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/327: Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

## Claims

### Claim 1

A microcapsule comprising a core encapsulated by a shell, wherein said core comprises a dispersion, wherein said dispersion comprises:
an oil phase comprising tretinoin in a solid form at a concentration of above 14% w/w in said oil phase; and
optionally at least one phase changing material;
wherein said at least one phase changing material is added to said dispersion, wherein said at least one phase changing material is not liquid at room temperature; wherein the tretinoin is the only active agent in said microcapsule.

### Claim 2 (depends on 1)

The microcapsule according to claim 1, wherein the shell is a metal oxide shell.

### Claim 3 (depends on 1)

The microcapsule according to claim 1, wherein the concentration of the tretinoin in said oil phase is between 15% to 25% by weight.

### Claim 4 (depends on 1)

The microcapsule according to claim 1, wherein the concentration of the tretinoin in said oil phase is between 17% to 25% by weight.

### Claim 5 (depends on 2)

The microcapsule according to claim 2, wherein the thickness of said metal oxide shell is ranging between 50 nm and 5000 nm according to EsB (energy selective backscattered-detector) micrograph.

### Claim 6 (depends on 1)

The microcapsule according to claim 1, wherein the average diameter of said microcapsule is in the range of between 5 micrometers and 50 micrometers according to EsB (energy selective backscattered-detector) micrograph.

### Claim 7 (depends on 1)

The microcapsule according to claim 1, wherein the tretinoin dissolution rate is between 5% to 35% weight/h as measured in a medium of 30%: 70% V/V mixture of water:isopropyl alcohol at about 32° C.

### Claim 8 (depends on 1)

The microcapsule according to claim 1, wherein said at least one phase changing material is selected from the group consisting of natural or synthetic paraffin, waxes, aliphatic alcohols, fatty acids, and any combination thereof, wherein said fatty acids have a formula of CH3(CH2)nCOOH, and wherein n is an integer from 10 to 100.

### Claim 9 (depends on 1)

The microcapsule according to claim 1, wherein said microcapsule is stable for a period of between about 2 weeks to about 2 years at room temperature.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the microcapsule according to claim 1, and a pharmaceutically acceptable carrier or excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the carrier is in a form of an ointment, a cream, a lotion, an oil, a solution, an emulsion, a gel, a paste, a milk, an aerosol, a powder or a foam.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the microencapsulation efficiency of the tretinoin is at least 90% by weight, wherein up to 10% by weight of the tretinoin is not encapsulated.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, wherein after two weeks storage at 40° C. and 75% relative humidity a concentration of all-trans 5,6-epoxy retinoic acid is less than 1% by weight of the initial tretinoin amount prior to storage.

### Claim 14 (depends on 1)

The microcapsule according to claim 1, wherein the shell is a silicon dioxide shell, and said microcapsule is prepared by a process comprising:
a. preparing an oil phase comprising:
mixing an oil medium with at least one antioxidant, a silica precursor and tretinoin to form an oil phase, wherein the concentration of the tretinoin in the oil phase is at least 14% w/w;
optionally, milling said oil phase;
optionally adding a phase changing material to said oil phase;
b. preparing an aqueous phase comprising mixing a surfactant and water;
c. preparing a sodium silicate solution comprising dissolving silicon dioxide and an inorganic base in water;
d. adding said oil phase to said aqueous phase to form an emulsion;
e. adding said sodium silicate solution to said emulsion;
f. adding acidic solution to said emulsion; and adjusting the pH to between 3.9 to 4.2;
forming a core comprising a dispersion of tretinoin encapsulated by a silicon dioxide shell.

### Claim 15 (depends on 14)

The microcapsule according to claim 14, wherein said silica precursor is TEOS, or wherein said antioxidant is butylated hydroxytoluene, or wherein said oil medium is squalane, or wherein said thickening agent is white beeswax, or wherein said surfactant is cetrimonium chloride, or any combination thereof.

### Claim 16 (depends on 14)

The microcapsule according to claim 14, wherein the microcapsules have microencapsulation efficiency of at least 90% by weight, wherein up to 10% by weight of the tretinoin is not encapsulated.

### Claim 17 (depends on 14)

The microcapsule according to claim 14, wherein the thickness of said metal oxide shell is ranging between 50 nm and 5000 nm according to EsB (energy selective backscattered-detector) micrograph.

### Claim 18 (depends on 14)

The microcapsule according to claim 14, wherein the average diameter of said microcapsule is ranging between 5 micrometers and 50 micrometers according to EsB (energy selective backscattered-detector) micrograph.

### Claim 19 (depends on 14)

The microcapsule according to claim 14, wherein the tretinoin dissolution rate is between 5% to 35% weight/h as measured in a medium of 30%: 70% V/V mixture of water:isopropyl alcohol at 32° C.

### Claim 20 (depends on 14)

The microcapsule according to claim 14, wherein said microcapsule is stable for a period of between about 2 weeks to about 2 years at room temperature.

### Claim 21 (depends on 14)

A pharmaceutical composition comprising the microcapsule according to claim 14, and a pharmaceutically acceptable carrier or excipient.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21, wherein the carrier is in a form of an ointment, a cream, a lotion, an oil, a solution, an emulsion, a gel, a paste, a milk, an aerosol, a powder or a foam.

### Claim 23 (depends on 21)

The pharmaceutical composition according to claim 21, wherein the microencapsulation efficiency of the tretinoin is at least 90% wherein up to 10% by weight of the tretinoin is not encapsulated.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising the microcapsule according to claim 1, wherein the tretinoin or a pharmaceutically acceptable salt thereof is in an amount of about 0.1% by weight of said composition and the composition further comprises a microcapsule comprising benzoyl peroxide, in an amount of about 3% by weight of said composition; and a pharmaceutically acceptable carrier or excipient.

### Claim 25 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the tretinoin dissolution rate is between 5% to 35% weight/h as measured in a medium of 30%: 70% V/V mixture of water:isopropyl alcohol at 32° C. and wherein the benzoyl peroxide dissolution rate is between 10% to 60% weight/h as measured in a medium of 55%: 45% mixture of water:acetonitrile at ambient temperature.

### Claim 26 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the benzoyl peroxide has microencapsulation efficiency of at least 75% by weight, wherein up to 25% by weight of the benzoyl peroxide is not encapsulated; and the tretinoin has microencapsulation efficiency of at least 90% by weight, wherein up to 10% by weight of the tretinoin is not encapsulated.

### Claim 27 (depends on 24)

The pharmaceutical composition according to claim 24, wherein after two weeks storage at 40° C. and 75% relative humidity a concentration of all-trans 5,6-epoxy retinoic acid is less than 1% by weight of the initial tretinoin amount prior to storage.
